Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koller, W. C.
Right arrow Articles by Klawans, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koller, W. C.
Right arrow Articles by Klawans, H. L.
NEUROLOGY 1981;31:473-476
© 1981 American Academy of Neurology

Complications of chronic levodopa therapy

Long-term efficacy Of drug holiday

William C. Koller, M.D., Ph.D., William J. Weiner, M.D., Stuart Perlik, M.D., Paul A. Nausieda, M.D., Christopher G. Goetz, M.D. and Harold L. Klawans, M.D.

From the Department of Neurological Sciences, Rush-Presbyterian St. Lukes Medical Center, Chicago, IL.

Address correspondence and reprint requests to Dr. Klawans, Department of Neurological Sciences, Rush-Presbyterian St. Lukes Medical Center, 1725 W. Harrison, Chicago, IL 60612.

Chronic use of levodopa may be complicated by dyskinesias, on-off effect, or hallucinosis. Transient levodopa withdrawal (drug holiday) may increase motor responsiveness and decrease levo-dopa-induced side effects, and the improved state may persist for as long as 9 months. After 1 year, parkinsonian signs approached pre-holiday levels, and two of the patients required a 'second drug holiday; side effects began to reappear 9 to 12 months after the holiday. Four of six patients with psychiatric complications remained free of hallucinations for the entire year.

This work was supported in part by grants from the United Parkinson Foundation and the Boothroyd Foundation, Chicago, IL.

Presented in part at the thirty-second annual meeting of the American Academy of Neurology, New Orleans, LA, May 1980.

Acknowledgment The authors wish to thank Richard B. Shekelle, Ph.D., Associate Professor, Department of Preventive Medicine, for assistance with data analysis.

Accepted for publication July 29, 1980.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1981 by AAN Enterprises, Inc.